Short-Acting Inhaled β2-Agonists: Why, Whom, What, How?

Andrzej Emeryk; Justyna Emeryk-Maksymiuk

doi:10.5603/ARM.a2020.0132

You are currently on the new version of our website. Access the old version .

Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.

Review

30 October 2020

Short-Acting Inhaled β2-Agonists: Why, Whom, What, How?

and

Department of Pediatric Pulmonology and Rheumatology Medical University in Lublin, Poland

Chair of Internal Medicine and Department of Internal Medicine in Nursing Medical University in Lublin, Poland

Author to whom correspondence should be addressed.

Adv. Respir. Med.2020, 88(5), 443-449;https://doi.org/10.5603/ARM.a2020.0132

Version Notes

Order Reprints

Abstract

We showed the present data about the efficacy and safety of inhaled short-acting β2-agonists (SABA), such as salbutamol and fenoterol, in the management of obstructive diseases in children and adults. Our work discusses major mechanisms of action, clinical effects, possible side effects and indications of inhaled SABA. We presented current recommendations for the position of SABA in the therapy of obstructive diseases in children and adults, particularly in asthma and chronic obstructive pulmonary disease.

Keywords:

short-acting β2-agonist; salbutamol; fenoterol; inhalation; nebulization; asthma; COPD

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Bronchoscopic Lung Volume Reduction Using Coil Therapy: Complications and Management

Early and Interdisciplinary Physiotherapy in a Patient in the Intensive Care Unit with a Bronchopulmonary Fistula after Thoracic Fenestration: A Case Report